Ben Sasse Co-Writes Book on Terminal Cancer
The former Nebraska senator, who has stage 4 pancreatic cancer, is co-authoring a book with his daughter Alex about his diagnosis.
Updated on Nov. 18, 2026 in Cancer

Former Nebraska U.S. Senator Ben Sasse revealed in a December 23, 2025, social media post that he has stage 4 pancreatic cancer. He and his daughter Alex Sasse have co-authored a book about navigating the diagnosis, titled "Redeem the Time."
Why it matters
Pancreatic cancer has a five-year survival rate of approximately 13%, and Sasse was initially given three to four months to live when diagnosed. His account offers a public look at how an advanced-stage patient is managing the disease and the treatment decisions that follow.
The reported 80% tumor shrinkage over five months reflects one patient's response in a clinical trial, which does not by itself establish the drug's effect across all patients. Sasse's case is an individual report, and the source does not state how long his response will last.
The players
Ben Sasse
Ben Sasse is a former U.S. Senator from Nebraska who previously served as president of the University of Florida.
U.S. Food and Drug Administration
The U.S. Food and Drug Administration is the federal agency responsible for approving drugs and medical treatments sold in the United States.
The details
Sasse's tumors shrank by 80% over five months while he took the oral drug daraxonrasib in a clinical trial. The FDA gave federal approval to daraxonrasib in late August 2026, and a recent liver surgery to remove tumors was considered a success, though tests showed the tumors were more advanced than initially thought and had mutated and developed resistance to the earlier treatment.
Timeline
December 23, 2025: Sasse revealed his pancreatic cancer diagnosis on social media.
Late August 2026: The FDA approved daraxonrasib for pancreatic cancer.
Late September 2026: Sasse reported the liver surgery success and tumor mutation findings.
March 9, 2027: The co-authored book "Redeem the Time" is scheduled for release.
Roadmap
Daraxonrasib's federal approval in August 2026 marks a shift in options for advanced pancreatic cancer, which has historically had poor survival rates. Sasse's experience shows both the early response to the newly approved oral drug and the emergence of resistance that is pushing treatment toward chemotherapy.
Readers facing advanced pancreatic cancer may note that the FDA-approved oral drug daraxonrasib produced a large tumor response in one patient, but resistance can develop and treatment may need to change. Anyone with questions about options should discuss current treatment and trial availability with their oncologist.
The takeaway
Sasse's account shows that a targeted oral therapy can shrink advanced pancreatic tumors significantly, yet tumors can mutate and stop responding, so patients should expect treatment plans to change over time. Discussing trial options and treatment updates with a care team early can help keep choices open.
What happens next
The co-authored book "Redeem the Time: The Strange Gift of Dying and the Lost Art of Living" is scheduled for release on March 9, 2027.
Further reading
For related coverage, explore Cancer news and updates across the Nebraska health section.






